BRPI0914927B8 - composto, composição farmacêutica e uso de um composto - Google Patents

composto, composição farmacêutica e uso de um composto

Info

Publication number
BRPI0914927B8
BRPI0914927B8 BRPI0914927A BRPI0914927A BRPI0914927B8 BR PI0914927 B8 BRPI0914927 B8 BR PI0914927B8 BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 A BRPI0914927 A BR PI0914927A BR PI0914927 B8 BRPI0914927 B8 BR PI0914927B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
medicines
cancer
function
Prior art date
Application number
BRPI0914927A
Other languages
English (en)
Inventor
Christophe Barlaam Bernard
David Jones Clifford
Michael Foote Kevin
Ple Patrick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0914927A2 publication Critical patent/BRPI0914927A2/pt
Publication of BRPI0914927B1 publication Critical patent/BRPI0914927B1/pt
Publication of BRPI0914927B8 publication Critical patent/BRPI0914927B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto. a presente invenção diz respeito a compostos que inibem a função cinase de adesão focal, processos para a sua preparação, composições farmacêuticas que as contenham como o ingrediente ativo, ao seu uso como medicamentos e ao seu uso na fabricação de medicamentos para o uso no tratamento em animais de sangue quente tais como seres humanos de doenças tais como câncer.
BRPI0914927A 2008-06-17 2009-06-15 composto, composição farmacêutica e uso de um composto BRPI0914927B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17
US61/073055 2008-06-17
PCT/GB2009/050675 WO2009153589A1 (en) 2008-06-17 2009-06-15 Pyridine compounds

Publications (3)

Publication Number Publication Date
BRPI0914927A2 BRPI0914927A2 (pt) 2017-06-20
BRPI0914927B1 BRPI0914927B1 (pt) 2020-10-06
BRPI0914927B8 true BRPI0914927B8 (pt) 2021-05-25

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914927A BRPI0914927B8 (pt) 2008-06-17 2009-06-15 composto, composição farmacêutica e uso de um composto

Country Status (17)

Country Link
US (1) US8569298B2 (pt)
EP (1) EP2303861B1 (pt)
JP (1) JP5551689B2 (pt)
KR (1) KR101695501B1 (pt)
CN (1) CN102124000B (pt)
AU (1) AU2009261764B2 (pt)
BR (1) BRPI0914927B8 (pt)
CA (1) CA2726508C (pt)
CR (1) CR11854A (pt)
DO (1) DOP2010000390A (pt)
EA (1) EA020807B1 (pt)
EC (1) ECSP10010695A (pt)
ES (1) ES2472323T3 (pt)
IL (1) IL209727A0 (pt)
MX (1) MX2010014057A (pt)
WO (1) WO2009153589A1 (pt)
ZA (1) ZA201100388B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3384482B2 (ja) 1997-03-18 2003-03-10 本田技研工業株式会社 ピストンリング供給装置
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
ES2642586T3 (es) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
JP5936609B2 (ja) 2010-06-29 2016-06-22 ベラステム インコーポレイテッド キナーゼインヒビターの経口製剤
EP2588476A4 (en) * 2010-06-30 2014-07-23 Verastem Inc SYNTHESIS AND USE OF KINASE INHIBITORS
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2667871A4 (en) * 2011-01-26 2014-07-09 Glaxosmithkline Intellectual Property Ltd COMBINATIONS
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (pt) 2011-07-01 2018-04-28
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
TN2016000529A1 (en) * 2014-06-17 2018-04-04 Pfizer Substituted dihydroisoquinolinone compounds
US9442005B2 (en) 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
TWI703133B (zh) 2014-12-23 2020-09-01 美商艾克斯基製藥公司 ３,５-二胺基吡唑激酶抑制劑
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
US10532056B2 (en) 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
EP3758491A1 (en) 2018-02-28 2021-01-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
IL276745B2 (en) 2018-02-28 2023-10-01 Basf Se Use of N-functional alkoxy pyrazole compounds as nitrification inhibitors
US20210030703A1 (en) 2018-03-12 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
KR102866499B1 (ko) * 2019-03-15 2025-10-02 더 제너럴 하스피탈 코포레이션 Tead 전사인자의 신규한 소분자 저해제
KR20220087497A (ko) * 2019-10-18 2022-06-24 더 리전츠 오브 더 유니버시티 오브 캘리포니아 병원성 혈관을 표적화하기 위한 화합물 및 방법
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
EP4341248A1 (en) 2021-05-21 2024-03-27 Basf Se Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
PT1660458E (pt) * 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
JP2008503561A (ja) 2004-06-21 2008-02-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 骨芽細胞機能を刺激するためのｐｙｋ２阻害薬
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2634646C (en) 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EP2727909A1 (en) * 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009012283A1 (en) * 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak

Also Published As

Publication number Publication date
CA2726508A1 (en) 2009-12-23
EP2303861A1 (en) 2011-04-06
IL209727A0 (en) 2011-02-28
KR20110023884A (ko) 2011-03-08
WO2009153589A1 (en) 2009-12-23
BRPI0914927A2 (pt) 2017-06-20
ZA201100388B (en) 2011-10-26
KR101695501B1 (ko) 2017-01-11
US20110166139A1 (en) 2011-07-07
JP5551689B2 (ja) 2014-07-16
CN102124000A (zh) 2011-07-13
JP2011524411A (ja) 2011-09-01
ECSP10010695A (es) 2011-01-31
EA201100032A1 (ru) 2012-01-30
EA020807B1 (ru) 2015-01-30
MX2010014057A (es) 2011-03-21
US8569298B2 (en) 2013-10-29
EP2303861B1 (en) 2014-04-23
AU2009261764B2 (en) 2013-01-10
DOP2010000390A (es) 2011-01-15
ES2472323T3 (es) 2014-06-30
HK1155170A1 (en) 2012-05-11
CR11854A (es) 2011-02-25
CA2726508C (en) 2016-06-07
CN102124000B (zh) 2014-09-17
AU2009261764A1 (en) 2009-12-23
BRPI0914927B1 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
BRPI0914927B8 (pt) composto, composição farmacêutica e uso de um composto
BRPI0611747A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo ou n-àxidos do mesmo, composiÇço farmacÊutica, mÉtodos para tratar uma infecÇço bacteriana e para inibir o dna girase bacteriana em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, processo para fabricar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
BRPI0507755A (pt) composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
BRPI0507790A (pt) composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
BRPI0808764B8 (pt) compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica
BRPI0514691A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0912475B8 (pt) compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica
BR112016002496A2 (pt) composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
BRPI0518126A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
RU2012157473A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
BR112014006223A2 (pt) 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met
BRPI0610090A2 (pt) terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UY30699A1 (es) Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF